The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
Precision intervention strategies in clonal hematopoiesis and CCUS
Kelly Bolton, MD, PhD, Washington University, St. Louis, MO, discusses precision intervention strategies for clonal hematopoiesis (CH) and clonal cytopenia of undetermined significance (CCUS) to prevent progression to myeloid malignancies. Dr Bolton highlights high-risk populations, including patients with germline predispositions and therapy-related CH, alongside promising findings from a decentralized trial of ivosidenib in IDH1-mutated CCUS. This presentation took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, DC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
